(Reuters) - British biotechnology firm Abcam Plc said on Monday it signed a deal with Roche Holding AG to get rights to a portfolio of the Swiss drugmaker’s research products in its life science division.
The Cambridge-based antibody maker said it would obtain the exclusive rights to brand and market a portfolio of 760 products that are for research use only (RUO) from Roche’s U.S.-based unit Spring Bioscience Corp.
Roche will retain the antibody development capabilities and rights pertaining to the Spring Portfolio for internal research, companion diagnostic and IVD uses.
Abcam said it was also granted RUO rights for all future products developed by Spring that Roche requests to be commercialized for an initial period of 10 years.
Shares of Abcam were up about 1.2 percent at 0851 GMT.
Reporting By Justin George Varghese in Bengaluru; Editing by Gopakumar Warrier